Investors & Media

Press Releases

Keyword Search

Nov
29
2023
Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND
Nov
03
2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Nov
02
2023
Cytokinetics Reports Third Quarter 2023 Financial Results
Nov
01
2023
Cytokinetics to Participate in Upcoming Investor Conferences
Oct
23
2023
Cytokinetics to Announce Third Quarter Results on November 2, 2023
Oct
19
2023
Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day
Oct
06
2023
Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions
Oct
05
2023
Cytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023
Oct
03
2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Oct
02
2023
Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
Sep
28
2023
Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program
Sep
07
2023
Cytokinetics to Participate in Upcoming Investor Conferences
Sep
06
2023
Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Sep
01
2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug
03
2023
Cytokinetics Reports Second Quarter 2023 Financial Results
Aug
01
2023
Cytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Jul
27
2023
Cytokinetics to Announce Second Quarter Results on August 3, 2023
Jul
05
2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun
20
2023
Cytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Jun
02
2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Jun
01
2023
Cytokinetics to Participate in Upcoming Investor Conferences
May
20
2023
Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress
May
15
2023
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress
May
11
2023
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586
May
08
2023
Cytokinetics to Participate in the JMP Securities Life Sciences Conference
May
04
2023
Cytokinetics Reports First Quarter 2023 Financial Results
May
03
2023
Cytokinetics to Hold Annual Meeting of Stockholders
May
01
2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr
20
2023
Cytokinetics to Announce First Quarter Results on May 4, 2023
Apr
10
2023
Cytokinetics To Participate In The 22nd Annual Needham Virtual Healthcare Conference
Apr
03
2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar
31
2023
Cytokinetics Announces COURAGE-ALS Met Criteria for Futility at Second Interim Analysis
Mar
27
2023
Cytokinetics Releases Inaugural Corporate Responsibility Report
Mar
06
2023
Cytokinetics to Participate in Upcoming Investor Conferences
Mar
04
2023
Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session
Mar
02
2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar
01
2023
Cytokinetics Reports Fourth Quarter 2022 Financial Results
Feb
28
2023
Cytokinetics Receives Complete Response Letter From FDA for New Drug Application for Omecamtiv Mecarbil
Feb
24
2023
Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session
Feb
22
2023
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
Feb
15
2023
Cytokinetics to Announce Fourth Quarter Results on March 1, 2023
Feb
01
2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan
30
2023
Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant Program
Jan
04
2023
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan
03
2023
Cytokinetics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

More Resources